• Damien Roos-Weil, Philippe Moreau, Hervé Avet-Loiseau, Jean-Louis Golmard, Mathieu Kuentz, Stéphane Vigouroux, Gérard Socié, Sabine Furst, Jean Soulier, Le GouillStevenS, Sylvie François, Anne Thiebaut, Agnès Buzyn, Natacha Maillard, Ibrahim Yakoub-Agha, Nicole Raus, Jean-Paul Fermand, Mauricette Michallet, Didier Blaise, Nathalie Dhédin, and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
• Hematology Department, University Hospital Pitié-Salpêtrière, Paris, France. damien.roosweil@psl.aphp.fr
• Haematologica. 2011 Oct 1; 96 (10): 1504-11.

BackgroundThe impact of cytogenetic abnormalities in multiple myeloma after allogeneic stem cell transplantation has not been clearly defined. This study examines whether allogeneic stem cell transplantation could be of benefit for myeloma patients with high-risk cytogenetic abnormalities.Design And MethodsThis is a retrospective multicenter analysis of the registry of the Société Française de Greffe de Moelle et de Thérapie Cellulaire, including 143 myeloma patients transplanted between 1999 and 2008.ResultsThe incidences of cytogenetic abnormalities were 59% for del(13q), 25% for t(4;14), 25% for del(17p) and 4% for t(14;16). When comparing the population carrying an abnormality to that without the same abnormality, no significant difference was found in progression-free survival, overall survival or progression rate. Patients were grouped according to the presence of any of the poor prognosis cytogenetic abnormalities t(4;14), del(17p) or t(14;16) (n=53) or their absence (n=32). No difference in outcomes was observed between these two groups: the 3-year progression-free survival, overall survival and progression rates were 30% versus 17% (P=0.9), 45% versus 39% (P=0.8) and 53% versus 75% (P=0.9), respectively.ConclusionsThese data indicate that allogeneic stem cell transplantation could potentially be of benefit to high-risk myeloma patients.

19 keywords...

hide…